Policy & Regulation
Imbrium Therapeutics LP and SpineThera Inc partnership doses first patient under Phase 1/2 sciatica clinical study
27 November 2019 -

Imbrium Therapeutics LP revealed on Tuesday that it has dosed the first patient under the SALIENT Phase 1/2 clinical study of SX600 for the treatment of sciatica, in partnership with SpineThera Inc.

SALIENT is a double-blind, randomized, placebo-controlled, parallel-group, first-in-human study evaluating the efficacy and safety of two doses (12.5 mg & 25 mg) of SX600 as a sustained-release, injectable treatment option for pain in and near the spine, added the companies.

In conjunction, Purdue has the exclusive option to acquire SpineThera Inc and gain worldwide rights to its products and technology platforms, including lead asset SX600, a non-opioid epidural steroid injection in development for the treatment of sciatica.

Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma LP.

Additionally, SpineThera develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. SX600, its lead product candidate, is an investigational drug. SpineThera Australia Pty Ltd is the sponsor of the SALIENT study.



Related Headlines